London-listed equities rose for a second consecutive day on Thursday, with the blue-chip FTSE 100 up 1.20% at closing, after the Bank of England kept its benchmark interest rate unchanged, as widely expected.
In a 6-3 vote, the UK's central bank maintained the bank rate at 3.75%, while three members voted for a 5-basis-point increase to 4%. The BoE cited a recent rise in consumer price inflation to 3.1% and expectations for further growth in the coming quarters. "The [Monetary Policy Committee] judges that it is appropriate to maintain Bank Rate at this meeting. The Committee stands ready to act as necessary to ensure that CPI inflation remains on track to meet the 2% target in the medium term," the central bank noted.
"Our base case remains for an unchanged Bank Rate until June 2027, when the BoE can resume the cutting cycle and deliver another 25bp rate cut. Bank Rate of 3.75% is already restrictive, and we are more sceptical about the growth outlook for the remainder of 2026. If energy markets do not improve and the economy continues to look resilient, we would then expect a rate hike, even in the absence of spillovers to broader price-setting," Danske Bank said.
On the corporate front, Next plc (NXT.L) rose 2.51% at closing after it reported year-over-year growth in its attributable profit and revenue for the 26 weeks to Aug. 1, 2026. For the fiscal year ending in January 2027, the British retailer forecast growth of 7% in total product sales, 6.7% in total full-price sales and 8.4% in group profit.
"NEXT has offered investors a strong online and cash-returns story historically. It should continue to benefit from its broad range of brands and strong omnichannel offer, with fast, highly automated logistics and a well-developed customer base. In recent years it has developed a strong international growth story driven by womens and menswear, and well targeted marketing in Europe, the Middle East and Rest of the World. We also think NEXT has potential to develop further its high-return Total Platform business for other brands, to leverage its strong systems and online warehousing and distribution," RBC Capital Markets said in its quick take note.
Elsewhere, AstraZeneca (AZN.L) and Japan's Daiichi Sankyo secured a recommendation from the UK's National Institute for Health and Care Excellence for Enhertu to treat adults with HER2-low advanced or metastatic breast cancer whose disease has progressed following treatment. AstraZeneca climbed 2.27% at closing.